Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MET | P08581 | 8/20 | 0.43 |
| ▸ | TK2 | O00142 | 4/20 | 0.38 |
| ▸ | TK1 | P04183 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12499643 | 0.87 | GAA (0.58) | GAAMETTK1DAOMEN1 | |
| SCHEMBL17243356 | 0.87 | GAA (0.58) | GAAMETTK1DAOMEN1 | |
| SCHEMBL12495880 | 0.85 | GAA (0.56) | GAAMETTK1DAOMEN1 | |
| SCHEMBL12410771 | 0.84 | GAA (0.62) | GAAMETTK1DAOMEN1 | |
| SCHEMBL17243371 | 0.83 | GAA (0.55) | GAAMETTK1DAOMEN1 | |
| SCHEMBL1558603 | 0.83 | GAA (0.55) | GAAMETDAOMEN1KMT2A | |
| SCHEMBL1558602 | 0.83 | GAA (0.55) | GAAMETDAOMEN1KMT2A | |
| SCHEMBL1558317 | 0.82 | GAA (0.53) | GAAMETCYP1A2CYP3A4NPSR1 | |
| SCHEMBL2183273 | 0.82 | GAA (0.53) | GAAMETCYP1A2CYP3A4NPSR1 | |
| SCHEMBL17243372 | 0.81 | GAA (0.58) | GAAMETTK1DAOMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181199-B2 | Uracil derivatives and use thereof | RESPROTECT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181199-B2 | Uracil derivatives and use thereof | RESPROTECT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| WO-2009156182-A2 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | TYMP, UNG, DPYD | GAA 2007/4885MET 4164/4885TK2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.